Published • loading... • Updated
EIT Pharma Presents Extended Phase 3 D-LIVR Trial Analyses at AASLD's The Liver Meeting® 2026
Summary by goSkagit
1 Articles
1 Articles
EIT Pharma Presents Extended Phase 3 D-LIVR Trial Analyses at AASLD's The Liver Meeting® 2026
KIRKLAND, Wash., Nov. 10, 2026 /PRNewswire/ -- EIT Pharma, Inc. ("EIT Pharma" or the "Company"), a biotechnology company focused on developing therapies for infectious diseases, today presented data at The Liver Meeting®, hosted by the American Association for the Study…
Coverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
